La Ciencia detrás de la vacunas contra SARS CoV-2

Edwin José Gutiérrez Ruiz, Roger Ivan Rodríguez Vivas, José Alberto Rosado Aguilar, Eduardo Gutiérrez Blanco, Manuel Emilio Bolio González

Resumen


.

Palabras clave


SARS CoV-2, vacunas

Texto completo:

PDF

Referencias


Brisse M, Vrba SM, Kirk N, Liang Y y Ly H. 2020. Emerging concepts and technologies in vaccine development. Frontiers in Immunology11:583077.

Dong Y, Dai T, Wei Y, Zhan L, Zheng M y Zhou F. 2020. A systematic review of SARS-CoV-2 vaccine candidates. Signal Transduction and Targeted Therapy 5: 237

Folegatti PM, Ewer KJ, Aley PK, et al. 2020. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet 396:467–478.

Gao Q., Bao L, Mao H, et al. 2020. Development of an inactivated vaccine candidate for SARS-CoV-2. Science 369:77–81.

Hall V, Foulkes S, Insalata F, et al. 2022. Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection. The New England Journal of Medicine 386: 2534-2535.

Jackson LA, Anderson EJ, Rouphael NG, et al. 2020. An mRNA Vaccine against SARS-CoV-2—preliminary report. New England Journal of Medicine. 383: 20

Ksiazek TG, Erdman D, Goldsmith CS, et al. 2003. A Novel Coronavirus associated with severe acute respiratory syndrome. The New England Journal of Medicine 348: 1953-1966.

Logunov DY, Dolzhikova IV, Zubkova OV, et al. 2020. Safety and immunogenicity of an rAd26 and rAd5 vector based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet.396: 887–897.

Moore KM, Jackwood MW, Hilt DA. 1996. Avian Infectious bronchitis virus:

RNArecombination in vitro. Proceedings of the 45th western Poultry Disease

Conference, Cancun, Mexico.

Muñoz Valle JF, Sánchez-Zuno GA, Matuz-Flores MG, et al. 2022. Efficacy and Safety of Heterologous Booster Vaccination after Ad5-nCoV (CanSino Biologics) Vaccine: A Preliminary Descriptive Study. Vaccines 10: 400.

Pardi N, Hogan MJ, Porter FW y Weissman, D. 2018. mRNA vaccines a new era in vaccinology. Nature Reviews Drug Discovery 17:261–279.

Ponce de León S, Torres M, Soto-Ramírez LE, et al. 2022. Safety and immunogenicity of a live recombinant Newcastle 1 disease virus-based 2 COVID-19 vaccine (Patria) administered via the intramuscular or intranasal 3 route: Interim results of a non-randomized open label phase I trial in Mexico. medRxiv preprint.

Rossi AH, Ojeda DS, Varese A, et al. 2021. Sputnik V vaccine elicits seroconversion and neutralizing capacity to SARS-CoV-2 after a single dose. Cell Reports Medicine 2.

Ulmer JB, Valley U y Rappuoli R. 2006. Vaccine manufacturing: challenges and solutions. Nature Biotechnology 24:1377–1383.

Wolff JA, Malone RW, Williams P, et al. 1990. Direct gene transfer into mouse muscle in vivo. Science 247:1465–1468.

Yu L, Wang Z, Jiang Y, et al. 2001. Molecular epidemiology of Infectious Bronchitis Virus isolates from China and South-East Asia. Avian Diseases 45: 201-209.

Zhang NN, Li XF, Deng YQ, et al. 2020. A Thermostable mRNA Vaccine against COVID-19. Cell 182:1271–1283.

Zhu FC, Li YH, Guan XH, et al. 2020. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet 395:1845–1854.




DOI: http://dx.doi.org/10.56369/BAC.4462

Bookmark and Share


Copyright (c) 2022 Bioagrociencias



Bioagrociencias, revista electrónica, es una publicación semestral editada por la Universidad Autónoma de Yucatán, a través de la Facultad de Medicina Veterinaria y Zootecnia, km. 15.5 carretera Mérida-Xmatkuil s/n, Mérida, Yucatán, México. Tel. 999 942 32 00. Editor Responsable: Alfonso Aguilar-Perera (alfonso.aguilar@correo.uady.mx) reserva del derecho al uso exclusivo, 04-2017-062617313100-203, ISSN 2007-431X.